共 827 条
[1]
Randolph TR(2005)Chronic myelocytic leukemia--Part II: Approaches to and molecular monitoring of therapy Clin Lab Sci 18 49-56
[2]
Hehlmann R(2003)Current CML therapy: progress and dilemma Leukemia 17 1010-1012
[3]
Saglio G(2004)Glivec and CML: a lucky date J Biol Regul Homeost Agents 18 246-251
[4]
Cilloni D(2002)Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study Blood 99 1928-1937
[5]
Rancati F(2002)Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study Blood 99 3530-3539
[6]
Boano L(2005)Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up Cancer 103 1659-1669
[7]
Talpaz M(2005)BCR-ABL gene amplification and overexpression in a patient with chronic myeloid leukemia treated with imatinib Cancer Genet Cytogenet 159 164-167
[8]
Silver RT(2005)RNAi-mediated knockdown of P-glycoprotein using a transposon-based vector system durably restores imatinib sensitivity in imatinib-resistant CML cell lines Exp Hematol 33 767-775
[9]
Druker BJ(2002)Determination of alpha-1 acid glycoprotein in patients with Ph+ chronic myeloid leukemia during the first 13 weeks of therapy with STI571 Blood Cells Mol Dis 28 75-85
[10]
Goldman JM(1975)[Active immunotherapy of acute leukemia and leukemic lymphosarcoma. Results of 10 years. Study of 200 cases] Nouv Presse Med 4 1337-1342